日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

ASK120067 potently suppresses B-cell or T-cell malignancies in vitro and in vivo by inhibiting BTK and ITK

ASK120067 通过抑制 BTK 和 ITK,在体外和体内均能有效抑制 B 细胞或 T 细胞恶性肿瘤。

Peiran Song ,Gang Bai ,Shingpan Chan ,Tao Zhang ,Linjiang Tong ,Yi Su ,Yanyan Shen ,Yi Chen ,Yingqiang Liu ,Mengzhen Lai ,Yi Ning ,Haotian Tang ,Yan Fang ,Yi Chen ,Ke Ding ,Jian Ding ,Hua Xie

JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo

JND4135 是一种新型 II 型 TRK 抑制剂,可在体内和体外克服 TRK xDFG 和其他突变的抗性

Jie Wang, Yang Zhou, Xia Tang, Xiuwen Yu, Yongjin Wang, Shingpan Chan, Xiaojuan Song, Zhengchao Tu, Zhimin Zhang, Xiaoyun Lu, Zhang Zhang, Ke Ding

GZD824 overcomes FGFR1-V561F/M mutant resistance in vitro and in vivo

GZD824 在体外和体内克服 FGFR1-V561F/M 突变体耐药性

Kaili Jiang, Xia Tang, Jing Guo, Rui He, Shingpan Chan, Xiaojuan Song, Zhengchao Tu, Yuting Wang, Xiaomei Ren, Ke Ding, Zhang Zhang

Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

发现新型第三代 EGFR 抑制剂并确定克服耐药性的潜在联合策略

Tao Zhang #, Rong Qu #, Shingpan Chan #, Mengzhen Lai, Linjiang Tong, Fang Feng, Hongyu Chen, Tingting Song, Peiran Song, Gang Bai, Yingqiang Liu, Yanan Wang, Yan Li, Yi Su, Yanyan Shen, Yiming Sun, Yi Chen, Meiyu Geng, Ke Ding, Jian Ding, Hua Xie

GZD824 as a FLT3, FGFR1 and PDGFRα Inhibitor Against Leukemia In Vitro and In Vivo

GZD824 作为 FLT3、FGFR1 和 PDGFRα 抑制剂在体内和体外对抗白血病

Yuting Wang, Lenghe Zhang, Xia Tang, Jinfeng Luo, Zhengchao Tu, Kaili Jiang, Xiaomei Ren, Fang Xu, Shingpan Chan, Yuhua Li, Zhang Zhang, Ke Ding